GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Withus Pharmaceutical Co Ltd (XKRX:330350) » Definitions » Net Income From Continuing Operations

Withus Pharmaceutical Co (XKRX:330350) Net Income From Continuing Operations : ₩4,412 Mil (TTM As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Withus Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Withus Pharmaceutical Co's net income from continuing operations for the three months ended in Mar. 2025 was ₩1,647 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was ₩4,412 Mil.

Withus Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for Withus Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Withus Pharmaceutical Co Net Income From Continuing Operations Chart

Withus Pharmaceutical Co Annual Data
Trend Jun19 Jun20 Dec21 Dec22 Dec23 Dec24
Net Income From Continuing Operations
Get a 7-Day Free Trial 8,038.60 4,263.80 2,479.16 7,959.18 4,784.74

Withus Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,019.26 -271.90 1,862.94 1,174.44 1,646.69

Withus Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩4,412 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Withus Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Withus Pharmaceutical Co Ltd (XKRX:330350) » Definitions » Net Income From Continuing Operations
Comparable Companies
XKRX:063160 XKRX:003060 XKRX:002620 XKRX:003120 XKRX:214390 XKRX:106190 XKRX:191420 XKRX:066700 XKRX:001360 XKRX:009300 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
9 Dongsan-ro 12-gil, Seocho-gu, 3rd, 4th, and 5th Floors of Withers Building, Seoul, KOR
Website
http://www.withuspharm.com
Withus Pharmaceutical Co Ltd is a pharmaceutical company. The firm is engaged in the manufacturing and selling of various medicines such as Broazette long-acting tablet, Wipina tablets, Mantini tablets, and Choline syrup among others.

Withus Pharmaceutical Co Headlines

No Headlines